Product Program year 2020 Source: CMS Open Payments

Gloperba

Drug Prophylaxis of gout flares in adults

NDC 72690-010-05

Open in the dashboard

General payments

$5,921

158 payments

Research payments

$0

0 payments

Through program year 2020, $5,921 in general payments and $0 in research payments were reported against Gloperba (Prophylaxis of gout flares in adults).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2020 General $2,171 156
2019 General $3,750 2

Breakdown

Who paid General payments · program years 2019–2020
  1. Avion Pharmaceuticals $5,921 158 payments
Top recipients General payments · program year 2020
  1. Alireza Nami Rheumatology · Charlotte, NC $39 2% · 2 payments
  2. John Grieveson Family Medicine · Lowell, MA $32 1% · 2 payments
  3. Zandra Rios-Rivera Internal Medicine · Latham, NY $29 1% · 2 payments
  4. Kimberly Peregrim Internal Medicine · Latham, NY $29 1% · 2 payments
  5. Hendrick Arnold Internal Medicine · Latham, NY $29 1% · 2 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2020.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2020
  1. Internal Medicine $832 38% · 53 practitioners
  2. Rheumatology Internal Medicine $763 35% · 51 practitioners
  3. Family Medicine $321 15% · 22 practitioners
  4. Nephrology Internal Medicine $148 7% · 10 practitioners
  5. Obstetrics & Gynecology $43 2% · 3 practitioners

The top 5 of 10 specialties; each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2020
  1. New York $544 25% · 32 recipients
  2. New Jersey $331 15% · 25 recipients
  3. Pennsylvania $261 12% · 19 recipients
  4. North Carolina $135 6% · 8 recipients
  5. California $123 6% · 7 recipients

The top 5 of 21 states; each share is of general payments naming this product in 2020 where a state was reported.

The top 25 states, free in the app

158 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record